강직성 척추염 치료제 시장 : 산업 규모, 점유율, 동향, 기회, 예측, 의약품별, 최종 용도별, 지역별, 경쟁별(2020-2030년)
Ankylosing Spondylitis Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug, By End Use, By Region & Competition, 2020-2030F
상품코드:1703468
리서치사:TechSci Research
발행일:2025년 04월
페이지 정보:영문 182 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
강직성 척추염(AS) 치료제 세계 시장 규모는 2024년 51억 달러에 달했고, 예측 기간 동안 견고한 성장세를 보이며 2030년까지 연평균 성장률(CAGR) 7.45%를 보일 것으로 예측됩니다.
시장 개요
예측 기간
2026-2030년
시장 규모 : 2024년
51억 달러
시장 규모 : 2030년
78억 7,000만 달러
CAGR : 2025-2030년
7.45%
급성장 부문
Humira
최대 시장
북미
강직성 척추염은 만성 염증성 자가면역질환으로 주로 척추를 침범하여 지속적인 통증, 뻣뻣함, 운동능력 저하를 유발하는 질환입니다. 척추 관절염의 일종으로 분류되는 AS는 말초 관절과 다양한 장기를 침범할 수 있으며, AS 치료제 시장은 임상연구의 발전, 새로운 치료법의 도입, 질환에 대한 전 세계 인식의 향상 등에 힘입어 최근 들어 괄목할 만한 발전을 거듭하고 있습니다.
AS는 척추 밑부분에 있는 천골과 골반을 연결하는 천장관절의 염증이 특징입니다. 이 염증이 장기화되면 척추의 척추뼈가 유합되어 척추의 유연성이 현저하게 제한되고 자세가 변하게 됩니다. 일반적으로 성인 초기에 발병하며, 흔한 증상으로는 요통과 아침의 뻣뻣함이 있습니다. 환자의 삶의 질을 향상시키기 위해서는 적시 진단과 효과적인 질병 관리가 필수적입니다.
강직성 척추염은 전 세계적으로 수백만 명이 앓고 있는 세계 건강 문제입니다. 유병률은 지역과 인구에 따라 다르며, 특히 HLA-B27 유전자를 중심으로 한 유전적 요인이 질병 발병에 큰 역할을 하며, AS 치료제 시장은 조기 진단, 치료 접근성 향상, 첨단 치료제의 등장으로 최근 몇 년동안 크게 성장하고 있습니다.
주요 시장 성장 촉진요인
강직성 척추염의 유병률 증가
AS의 조기 진단이 가능해짐에 따라 조기 치료 개입이 가능해져 장기적인 치료 지속성이 향상되고, 치료 제품에 대한 지속적인 수요가 증가하고 있습니다.
Global Ankylosing Spondylitis (AS) therapeutics market was valued at USD 5.10 billion in 2024 and is expected to witness robust growth during the forecast period, registering a compound annual growth rate (CAGR) of 7.45% through 2030.
Market Overview
Forecast Period
2026-2030
Market Size 2024
USD 5.10 Billion
Market Size 2030
USD 7.87 Billion
CAGR 2025-2030
7.45%
Fastest Growing Segment
Humira
Largest Market
North America
Ankylosing spondylitis is a chronic, inflammatory autoimmune disorder that predominantly affects the spine, leading to persistent pain, stiffness, and reduced mobility. Classified within the group of spondyloarthritis disorders, AS can also involve peripheral joints and various organs. The market for AS therapeutics has experienced notable progress in recent years, fueled by advancements in clinical research, the introduction of novel treatment modalities, and increased global awareness of the disease.
AS is marked by inflammation of the sacroiliac joints, connecting the sacrum at the base of the spine to the pelvis. Over time, this inflammation can result in the fusion of spinal vertebrae, severely limiting spinal flexibility and altering posture. Typically manifesting in early adulthood, common symptoms include lower back pain and morning stiffness. Timely diagnosis and effective disease management are essential to enhancing patients' quality of life.
Ankylosing spondylitis is a global health concern, affecting millions of individuals worldwide. Prevalence rates vary by region and population, with genetic factors-particularly the HLA-B27 gene-playing a major role in disease development. The AS therapeutics market has expanded considerably in recent years due to earlier diagnoses, increased treatment accessibility, and the availability of advanced therapeutics.
Key Market Drivers
Rising Prevalence of Ankylosing Spondylitis
The increasing global incidence of ankylosing spondylitis is a primary driver of market growth. Although AS affects a relatively small proportion of the population-ranging from 0.1% to 1.4%-its impact is significant, particularly among males and individuals in their most productive working years, often beginning in their mid-20s.
This growing patient base is intensifying the demand for effective, long-term therapeutic solutions, creating ample opportunities for pharmaceutical manufacturers and healthcare providers. Traditionally underdiagnosed due to its insidious onset and nonspecific symptoms, AS is now being identified earlier thanks to heightened awareness and advancements in diagnostic imaging technologies.
The ability to diagnose AS in its early stages enables earlier intervention, which enhances long-term treatment adherence and drives sustained demand for therapeutic products.
Key Market Challenges
Limited Awareness and Delayed Diagnosis
One of the core challenges faced by the AS therapeutics market is the limited awareness among both healthcare professionals and the general public. Misdiagnosis or late diagnosis remains a common issue, often resulting in delayed treatment and worsened patient outcomes. Addressing this gap through education and awareness campaigns is vital to improving early detection and disease management.
Key Market Trends
Technological Advancements in Diagnosis and Treatment
Emerging technologies have significantly improved the diagnostic accuracy and management of ankylosing spondylitis. Imaging techniques such as magnetic resonance imaging (MRI) and computed tomography (CT) are now routinely employed to detect early signs of inflammation and structural damage in the spine and sacroiliac joints. These high-resolution tools facilitate early diagnosis, which is crucial for initiating timely treatment.
Additionally, the integration of artificial intelligence (AI) and machine learning in image analysis has enhanced diagnostic precision. AI-driven tools are capable of identifying subtle pathological changes that might be overlooked by human evaluators, further supporting early and accurate diagnosis.
On the treatment front, advancements in biotechnology have led to the development of biological therapies-targeted drugs that address the specific immune mechanisms driving AS-related inflammation. TNF inhibitors have significantly improved patient outcomes by alleviating pain, stiffness, and inflammation. Furthermore, the emergence of biosimilars-cost-effective alternatives to biologic drugs-has broadened patient access to these life-changing treatments, especially in cost-sensitive markets.
Key Market Players
AbbVie, Inc.
Amgen, Inc.
Pfizer, Inc.
Novartis AG
Eli Lilly and Company
UCB, Inc.
Johnson & Johnson Services, Inc.
Merck & Co., Inc
Report Scope:
In this report, the Global Ankylosing Spondylitis Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Ankylosing Spondylitis Therapeutics Market, By Drug:
Cosentyx
Humira
Simponi
Remicade
Enbrel
Cimzia
Ankylosing Spondylitis Therapeutics Market, By End Use:
Hospitals
Clinics
Others
Ankylosing Spondylitis Therapeutics Market, By Region:
North America
United States
Canada
Mexico
Europe
France
United Kingdom
Italy
Germany
Spain
Asia-Pacific
China
India
Japan
Australia
South Korea
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Ankylosing Spondylitis Therapeutics Market.
Available Customizations:
Global Ankylosing Spondylitis Therapeutics market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Ankylosing Spondylitis Therapeutics Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Drug (Cosentyx, Humira, Simponi, Remicade, Enbrel, Cimzia)
5.2.2. By End Use (Hospitals, Clinics, Others)
5.2.3. By Region
5.2.4. By Company (2024)
5.3. Market Map
6. North America Ankylosing Spondylitis Therapeutics Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Drug
6.2.2. By End Use
6.2.3. By Country
6.3. North America: Country Analysis
6.3.1. United States Ankylosing Spondylitis Therapeutics Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Drug
6.3.1.2.2. By End Use
6.3.2. Canada Ankylosing Spondylitis Therapeutics Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Drug
6.3.2.2.2. By End Use
6.3.3. Mexico Ankylosing Spondylitis Therapeutics Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Drug
6.3.3.2.2. By End Use
7. Europe Ankylosing Spondylitis Therapeutics Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Drug
7.2.2. By End Use
7.2.3. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Ankylosing Spondylitis Therapeutics Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Drug
7.3.1.2.2. By End Use
7.3.2. United Kingdom Ankylosing Spondylitis Therapeutics Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Drug
7.3.2.2.2. By End Use
7.3.3. Italy Ankylosing Spondylitis Therapeutics Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Drug
7.3.3.2.2. By End Use
7.3.4. France Ankylosing Spondylitis Therapeutics Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Drug
7.3.4.2.2. By End Use
7.3.5. Spain Ankylosing Spondylitis Therapeutics Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Drug
7.3.5.2.2. By End Use
8. Asia-Pacific Ankylosing Spondylitis Therapeutics Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Drug
8.2.2. By End Use
8.2.3. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Ankylosing Spondylitis Therapeutics Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Drug
8.3.1.2.2. By End Use
8.3.2. India Ankylosing Spondylitis Therapeutics Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Drug
8.3.2.2.2. By End Use
8.3.3. Japan Ankylosing Spondylitis Therapeutics Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Drug
8.3.3.2.2. By End Use
8.3.4. South Korea Ankylosing Spondylitis Therapeutics Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Drug
8.3.4.2.2. By End Use
8.3.5. Australia Ankylosing Spondylitis Therapeutics Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Drug
8.3.5.2.2. By End Use
9. South America Ankylosing Spondylitis Therapeutics Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Drug
9.2.2. By End Use
9.2.3. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Ankylosing Spondylitis Therapeutics Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Drug
9.3.1.2.2. By End Use
9.3.2. Argentina Ankylosing Spondylitis Therapeutics Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Drug
9.3.2.2.2. By End Use
9.3.3. Colombia Ankylosing Spondylitis Therapeutics Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Drug
9.3.3.2.2. By End Use
10. Middle East and Africa Ankylosing Spondylitis Therapeutics Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Drug
10.2.2. By End Use
10.2.3. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Ankylosing Spondylitis Therapeutics Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Drug
10.3.1.2.2. By End Use
10.3.2. Saudi Arabia Ankylosing Spondylitis Therapeutics Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Drug
10.3.2.2.2. By End Use
10.3.3. UAE Ankylosing Spondylitis Therapeutics Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Drug
10.3.3.2.2. By End Use
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Recent Developments
12.2. Product Launches
12.3. Mergers & Acquisitions
13. Global Ankylosing Spondylitis Therapeutics Market: SWOT Analysis
